Both the abnormal bodies and many of the symptoms are associated with Parkinson's disease and Alzheimer's, the institute points out, so scientists do not know whether the ailment is a distinct disease or a variant of Alzheimer's or Parkinson's.
Amgen's decision reverberated beyond the 48 patients in the trials because the drug, called glial cell line-derived neurotrophic factor, or GDNF, had the potential to stall or even reverse the progression of the disease rather than just reduce the symptoms, as the currently available Parkinson's drugs do.
